Artelo Biosciences, Inc. (NASDAQ:ARTL) Receives Average Recommendation of “Buy” from Brokerages

Artelo Biosciences, Inc. (NASDAQ:ARTL) has earned an average recommendation of “Buy” from the five brokerages that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $24.00.

Several equities research analysts recently commented on ARTL shares. D. Boral Capital reiterated a “hold” rating on shares of Artelo Biosciences in a report on Monday. Wall Street Zen downgraded shares of Artelo Biosciences to a “strong sell” rating in a research report on Saturday, August 9th. Finally, D Boral Capital downgraded Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday.

Artelo Biosciences Stock Performance

NASDAQ:ARTL opened at $4.68 on Wednesday. The firm has a market cap of $3.29 million, a P/E ratio of -0.25 and a beta of 1.46. Artelo Biosciences has a fifty-two week low of $4.20 and a fifty-two week high of $28.60. The firm has a 50-day simple moving average of $11.67 and a two-hundred day simple moving average of $8.05.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($5.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($5.48). On average, equities research analysts predict that Artelo Biosciences will post -2.62 EPS for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.